Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.

Passante, Maria; Napolitano, Maddalena; Dastoli, Stefano; Bennardo, Luigi; Fabbrocini, Gabriella; Nisticò, Steven Paul; Patruno, Cataldo

Passante, Maria; Napolitano, Maddalena; Dastoli, Stefano; Bennardo, Luigi; Fabbrocini, Gabriella; Nisticò, Steven Paul; Patruno, Cataldo.

Passante M; Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Napolitano M; Department of Health Sciences V. Tiberio, University of Molise, Campobasso, Italy.
Dastoli S; Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Bennardo L; Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Fabbrocini G; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Nisticò SP; Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Patruno C; Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

Dermatol Ther ; 34(6): e15111, 2021 11.

Article in English | MEDLINE | ID: covidwho-1370866

Subject(s)

Anti-Allergic Agents; COVID-19; Chronic Urticaria; Urticaria; Anti-Allergic Agents/adverse effects; Chronic Disease; Humans; Omalizumab/adverse effects; SARS-CoV-2; Treatment Outcome; Urticaria/diagnosis; Urticaria/drug therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Urticaria / Anti-Allergic Agents / Chronic Urticaria / COVID-19 Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2021 Document Type: Article Affiliation country: Dth.15111

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google